-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 8, Cinda Biopharmaceuticals announced its glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) dual agonist The Phase II clinical study of IBI362 in diabetic subjects completed the first subject administration
This study is a randomized, multi-center phase II clinical study evaluating the efficacy and safety of IBI362 relative to placebo and dulaglutide in Chinese patients with type 2 diabetes.
Note: The original text has been deleted